Does inflammation markers or treatment type moderate exercise intensity effects on changes in muscle strength in cancer survivors participating in a 6-month combined resistance- and endurance exercise program? Results from the Phys-Can trial

Anna Henriksson,Emelie Strandberg,Andreas Stenling,Anne-Sophie Mazzoni,Katarina Sjövall,Sussanne Börjeson,Truls Raastad,Ingrid Demmelmaier,Sveinung Berntsen,Karin Nordin
DOI: https://doi.org/10.1186/s13102-023-00617-3
2023-01-20
Abstract:Resistance exercise has a beneficial impact on physical function for patients receiving oncological treatment. However, there is an inter-individual variation in the response to exercise and the tolerability to high-intensity exercise. Identifying potential moderating factors, such as inflammation and treatment type, for changes in muscle strength is important to improve the effectiveness of exercise programs. Therefore, we aimed to investigate if inflammation and type of oncological treatment moderate the effects of exercise intensity (high vs. low-moderate) on muscular strength changes in patients with breast (BRCA) or prostate cancer (PRCA).
rehabilitation,sport sciences
What problem does this paper attempt to address?